The COVID-19 pandemic that struck the world last year is still spreading rapidly across the globe, putting a strain on the health care system. Currently, there are 22,106,557 COVID-19 infected patients in need of some specific rehabilitation therapies.

VR4REHAB organizes an audition process that will see some of Europe's best developers compete to create products that use virtual reality, augmented reality, and digital technology to help rehabilitate people who have suffered from COVID-19.

The Master of Digital Health, MDH (formerly - Master of Medical Informatics, MMI) at European Campus Rottal-Inn (ECRI) - a branch of the Deggendorf University of Applied Sciences (DIT) in Bavaria, Germany - is now accepting applications for entry in October 2021.

Smart health technology provider Alcidion Group has today announced the strategic acquisition of ExtraMed, a UK company which specialises in providing NHS trusts with software that helps frontline staff make informed decisions based on real-time visibility of patient flow.

Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the vision-based patient monitoring and management platform delivered as software as a service.

CliniSys Group has created a single brand for its businesses in the UK and Europe, with a refreshed logo and a new website.

The move creates a unified identity for CliniSys in the UK and MIPS on the continent and underlines the group's commitment to providing end-to-end diagnostic systems to support safe and effective healthcare systems today and to drive medical innovation in the future.

Thousands of NHS professionals across five hospitals in East Lancashire are to benefit from early warning technology that will help them detect and swiftly respond to deteriorating patients in need of urgent attention.

Alcidion's Patientrack system will help staff intervene early to prevent harm when patients show signs of worsening conditions.

Elsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further refined and extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process.